Humoral immune response to human papillomavirus infection.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Clinical Dermatology

• Publication date

  1997-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0738-081X(96)00166-6PMID 9167909
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer

  2006cited by this paper
• Cofactors with human papillomavirus in a population-based study of vulvar cancer.

  1997cited by this paper
• Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men.

  1997cited by this paper
• Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior.

  1996cited by this paper
• Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas.

  1996cited by this paper
• Protection against papillomavirus with a polynucleotide vaccine.

  1996cited by this paper
• Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA

  1996cited by this paper
• The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection.

  1996cited by this paper
• Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens.

  1996cited by this paper
• In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype

  1996cited by this paper
• Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

  1996cited by this paper
• Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice.

  1996cited by this paper
• Immunology of papillomavirus infection.

  1996cited by this paper
• Serological response to HPV16 in CIN‐III and cervical‐cancer patients. Case‐control studies in Spain and Colombia

  1996cited by this paper
• The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

  1996cited by this paper
• Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.

  1996cited by this paper
• Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups.

  1996cited by this paper
• Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China.

  1996cited by this paper
• Laboratory production of infectious stocks of rabbit oral papillomavirus.

  1996cited by this paper
• The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer.

  1996cited by this paper
• Human papillomavirus-specific serologic response in vulvar neoplasia.

  1996cited by this paper
• Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study

  1996cited by this paper
• Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11

  1996cited by this paper
• Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro.

  1995cited by this paper
• Human papillomavirus type 11 E1--E4 and L1 proteins colocalize in the mouse xenograft system at multiple time points.

  1995cited by this paper
• Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

  1995cited by this paper
• Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups.

  1995cited by this paper
• Serum Antibody against Unfused Recombinant E7 Protein of Human Papillomavirus Type 16 in Cervical Cancer Patients

  1995cited by this paper
• Absence of human papillomavirus DNA detected by polymerase chain reaction in French patients with esophageal carcinoma.

  1995cited by this paper
• Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts

  1995cited by this paper
• Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins.

  1995cited by this paper
• Papilloma formation in human foreskin xenografts after inoculation of human papillomavirus type 16 DNA

  1995cited by this paper
• Follow‐up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma

  1995cited by this paper
• Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma

  1995cited by this paper
• Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective

  1995cited by this paper
• Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.

  1995cited by this paper
• Rare association of human papillomavirus DNA with esophageal cancer in Japan.

  1995cited by this paper
• Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts.

  1995cited by this paper
• Development and characterization of a novel xenograft model permissive for human papillomavirus DNA amplification and late gene expression.

  1995cited by this paper
• Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia.

  1995cited by this paper
• Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection.

  1995cited by this paper
• Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer.

  1995cited by this paper
• Antibodies to the E4, E6, and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated diseases and in the normal population.

  1995cited by this paper
• Human Papillomavirus Type 11 E1 up angle E4 and L1 Proteins Colocalize in the Mouse Xenograft System at Multiple Time Points

  1995cited by this paper
• Divergent human papillomavirus type 16 variants are serologically cross-reactive.

  1995cited by this paper
• Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection

  1995cited by this paper
• Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape.

  1995cited by this paper
• Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

  1995cited by this paper
• Evaluation of temperature sensitivity of human papillomavirus type 11 by using the human xenograft severe combined immunodeficiency mouse model

  1994cited by this paper
• A population-based seroepidemiological study of cervical cancer.

  1994cited by this paper
• Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls.

  1994cited by this paper
• Human papillomaviruses.

  1994cited by this paper
• Colocalization of Human Papillomavirus Type 11 E1^E4 and L1 Proteins in Human Foreskin Implants Grown in Athymic Mice

  1994cited by this paper
• Prognostic significance of serum antibodies to human papillomavirus‐16 E4 and E7 peptides in cervical cancer

  1994cited by this paper
• Human Pathogenic Papillomavirus Types: An Update

  1994cited by this paper
• Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts.

  1994cited by this paper
• Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

  1994cited by this paper
• Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.

  1994cited by this paper
• Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.

  1994cited by this paper
• Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.

  1994cited by this paper
• Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids

  1994cited by this paper
• Human pathogenic papillomavirus types: an update.

  1994cited by this paper
• Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins

  1994cited by this paper
• Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil.

  1994cited by this paper
• Colocalization of human papillomavirus type 11 E1[symbol: see text]E4 and L1 proteins in human foreskin implants grown in athymic mice.

  1994cited by this paper
• Human papillomaviruses.

  1994cited by this paper
• A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

  1994cited by this paper
• Interaction of papillomaviruses with the cell surface

  1994cited by this paper
• Antibodies against papillomavirus antigens in cervical secretions from condyloma patients

  1993cited by this paper
• Determinants of Genital Human Papillomavirus Infection in Low‐Risk Women in Portland, Oregon

  1993cited by this paper
• Determinants of Genital Human Papillomavirus Infection in Low‐Income Women in Washington, D.C

  1993cited by this paper
• Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia.

  1993cited by this paper
• Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model.

  1993cited by this paper
• Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins

  1993cited by this paper
• Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma

  1993cited by this paper
• HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts.

  1993cited by this paper
• Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA

  1993cited by this paper
• Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles

  1993cited by this paper
• The association of human papillomavirus antibodies with cervical cancer risk.

  1992cited by this paper
• A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

  1992cited by this paper
• Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP).

  1992cited by this paper
• Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

  1992cited by this paper
• Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions.

  1992cited by this paper
• Identification of Antibodies against Human Papillomavirus Type 16 E6 and E7 Proteins in Sera of Patients with Cervical Neoplasias

  1992cited by this paper
• Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer.

  1992cited by this paper
• Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF.

  1992cited by this paper
• Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia.

  1992cited by this paper
• Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs.

  1992cited by this paper
• Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation.

  1992cited by this paper
• Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer.

  1992cited by this paper
• Serological assays for the detection of HPV antibodies.

  1992cited by this paper
• Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

  1991cited by this paper
• Genital human papillomavirus infection in female university students as determined by a PCR‐based method

  1991cited by this paper
• The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes.

  1991cited by this paper
• Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions.

  1991cited by this paper
• Comparison of neutralization of BPV‐1 infection of C127 cells and bovine fetal skin xenografts

  1991cited by this paper
• Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata.

  1991cited by this paper
• Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation

  1991cited by this paper
• Human Papillomavirus Genital Tract Infections During Pregnancy

  1990cited by this paper
• Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls.

  1990cited by this paper

• Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus

  2020cites this paper
• Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination

  2020cites this paper
• Natural history of human papillomavirus and vaccinations in men: A literature review

  2019cites this paper
• Serodiagnosis for tumor viruses.

  2015cites this paper
• Replication of human papillomavirus in culture.

  2015cites this paper
• The Transcription Map of Human Papillomavirus Type 18 during Genome Replication in U2OS Cells

  2014cites this paper
• Serological markers for papillomavirus infection and skin tumour development in the rodent model Mastomys coucha.

  2011influential citation
• Development of a Cellular Assay System To Study the Genome Replication of High- and Low-Risk Mucosal and Cutaneous Human Papillomaviruses

  2011cites this paper
• Human Papillomavirus and Head and Neck Cancer

  2010cites this paper
• Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China

  2010cites this paper
• Human papillomavirus (HPV) in mothers before and after delivery – a three year follow-up study.

  2009cites this paper
• Serological study in Tunisian cervical cancer patients.

  2009cites this paper
• Detection of HPV types and neutralizing antibodies in Gansu province, China

  2009cites this paper
• Does Pretreatment Seropositivity to Human Papillomavirus Have Prognostic Significance for Head and Neck Cancers?

  2008cites this paper
• Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.

  2008cites this paper
• Differentiation of xenografted human fetal lung parenchyma.

  2008cites this paper
• Seroepidemiology as basis for design of a human papillomavirus vaccination program.

  2008cites this paper
• Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors

  2007cites this paper
• Human papillomavirus seropositivity and risks of head and neck cancer

  2007cites this paper
• An inhibitor of the epidermal growth factor receptor function does not affect the ability of human papillomavirus 11 to form warts in the xenografted immunodeficient mouse model.

  2007cites this paper
• The level of antibody against E6 HPV 16 oncoprotein in blood sera of women with chronic HPV 16 infection and cervical cancer.

  2006cites this paper
• Public Health Implications of Human Papilloma Virus Vaccination: With Reference to the German Situation

  2006cites this paper
• Prevalence and Clustering Patterns of Human Papillomavirus Genotypes in Multiple Infections

  2005cites this paper
• Lack of serologic evidence for prevalent simian virus 40 infection in humans.

  2004influential citation
• Oral Opportunistic Infections in HIV-Positive Individuals: Review and Role of Mucosal Immunity

  2004cites this paper
• Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity

  2004cites this paper
• Efficient Intracellular Assembly of Papillomaviral Vectors

  2004cites this paper
• Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

  2004cites this paper
• The Role Of Human Papillomavirus (HPV) And The Increasing Incidence Of Oral Pathology In The Era Of Highly Active Antiretroviral Therapy (HAART)

  2004cites this paper
• HIV-1 Infection in a Small Animal Human Vaginal Xenograft Model

  2003cites this paper
• Serology for human papillomavirus.

  2003cites this paper
• Human Papillomavirus-Specific Antibody Status in Oral Fluids Modestly Reflects Serum Status in Human Immunodeficiency Virus-Positive Individuals

  2003cites this paper
• Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals.

  2003cites this paper
• Evasion of host immunity directed by papillomavirus-encoded proteins.

  2002cites this paper
• A population-based study of squamous cell vaginal cancer: HPV and cofactors.

  2002cites this paper
• Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection

  2001cites this paper
• Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients

  2001cites this paper
• Immunity to human papillomaviruses: Implications for vaccine design

  2001cites this paper
• Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.

  2001cites this paper
• Immunological characterization of human vaginal xenografts in immunocompromised mice: development of a small animal model for the study of human immunodeficiency virus-1 infection.

  2001cites this paper
• Production of infectious bovine papillomavirus from cloned viral DNA by using an organotypic raft/xenograft technique.

  2000cites this paper
• Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

  2000cites this paper
• Infection with human papillomavirus: Update on epidemiology, diagnosis, and treatment

  2000influential citation
• The immunology of animal papillomaviruses.

  2000cites this paper
• The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer.

  2000cites this paper
• Seroprevalence of human papillomavirus type 16 in pregnant women.

  1999cites this paper
• [Biology of papillomavirus infections. IV. Sero-epidemiological data].

  1999cites this paper
• Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection.

  1998cites this paper
• Disseminated mucosal papilloma/condyloma secondary to human papillomavirus.

  1998cites this paper
• Therapeutic evaluation of compounds in the SCID-RA papillomavirus model.

  1998cites this paper
• Presence of antibodies to human papillomavirus virus‐like particles (VLPs) in 11–13‐year‐old schoolgirls

  1998cites this paper
• Human papillomaviruses: general features.

  1997cites this paper
• [Human papillomaviruses and carcinogenesis of the uterine cervix: future prospects in the domain of detection and prevention].

  1997cites this paper